Building the foundations for faster progress against brain cancer

Uniting researchers, clinicians and patients to accelerate research and improve patient care.
Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium

Building the foundations for faster progress against brain cancer

July 1, 2026
Uniting researchers, clinicians and patients to accelerate research and improve patient care.
Read Transcript

The challenge

Brain cancer remains the leading cause of cancer death in children and adults under 40, yet survival outcomes have changed little in the past four decades. Progress has been slowed by fragmented data, limited access to biospecimens and tumour models, costly clinical trials, challenges recruiting patients into research, and variation in care across Australia.

 

To address these barriers, Brain Cancer Australia is developing three nationally coordinated research infrastructure platforms designed to give everyone who can help defeat brain cancer what they need to do it.

"This is not about a single research project; this is about enabling the whole system to work better, improving consistency of care, accelerating research, and lifting survival rates."

Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium

The role of philanthropy

The three platforms include the Australian Brain Cancer Registry (ABCR), the Opt Me In Platform, and the Biobanking and Organoid Platform. Together, they will provide the national infrastructure that all clinicians and researchers need to tackle the challenges of brain cancer collaboratively and effectively.

This collaboration brings together 47 leading brain cancer clinicians and researchers from 33 institutions, alongside 12 partner organisations, creating the largest collaborative brain cancer research project ever established in Australia.  Hearts & Minds funding has played a critical role in establishing this national collaboration by supporting the coordination, governance, stakeholder engagement and partnerships needed to build and sustain these platforms. These essential activities underpin long-term research success but are rarely funded through traditional research grants.

The platforms are already demonstrating their potential to improve research and care. For example, the ABCR is helping identify variation in clinical care. Early reporting highlighted an opportunity to improve treatment by identifying older patients who were not receiving the recommended dose of radiotherapy, enabling targeted action.

What this could unlock

Once complete, the three platforms will create a nationally coordinated infrastructure ecosystem to support brain cancer research and care. This will help enable more cost-effective clinical trials, faster translation of research into treatments, greater collaboration between researchers, clinicians and patients, improved access to research opportunities, and more consistent care across Australia. It is also expected to strengthen Australia's ability to attract international research investment and partnerships. Ultimately, this work aims to improve survival outcomes for people diagnosed with brain cancer.

Funding support from Hearts & Minds and Core Fund Manager TDM Growth Partners. This content was last updated in July 2026. For further information, visit Brain Cancer Australia.

The challenge

Brain cancer remains the leading cause of cancer death in children and adults under 40, yet survival outcomes have changed little in the past four decades. Progress has been slowed by fragmented data, limited access to biospecimens and tumour models, costly clinical trials, challenges recruiting patients into research, and variation in care across Australia.

 

To address these barriers, Brain Cancer Australia is developing three nationally coordinated research infrastructure platforms designed to give everyone who can help defeat brain cancer what they need to do it.

"This is not about a single research project; this is about enabling the whole system to work better, improving consistency of care, accelerating research, and lifting survival rates."

Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium

The role of philanthropy

The three platforms include the Australian Brain Cancer Registry (ABCR), the Opt Me In Platform, and the Biobanking and Organoid Platform. Together, they will provide the national infrastructure that all clinicians and researchers need to tackle the challenges of brain cancer collaboratively and effectively.

This collaboration brings together 47 leading brain cancer clinicians and researchers from 33 institutions, alongside 12 partner organisations, creating the largest collaborative brain cancer research project ever established in Australia.  Hearts & Minds funding has played a critical role in establishing this national collaboration by supporting the coordination, governance, stakeholder engagement and partnerships needed to build and sustain these platforms. These essential activities underpin long-term research success but are rarely funded through traditional research grants.

The platforms are already demonstrating their potential to improve research and care. For example, the ABCR is helping identify variation in clinical care. Early reporting highlighted an opportunity to improve treatment by identifying older patients who were not receiving the recommended dose of radiotherapy, enabling targeted action.

What this could unlock

Once complete, the three platforms will create a nationally coordinated infrastructure ecosystem to support brain cancer research and care. This will help enable more cost-effective clinical trials, faster translation of research into treatments, greater collaboration between researchers, clinicians and patients, improved access to research opportunities, and more consistent care across Australia. It is also expected to strengthen Australia's ability to attract international research investment and partnerships. Ultimately, this work aims to improve survival outcomes for people diagnosed with brain cancer.

Funding support from Hearts & Minds and Core Fund Manager TDM Growth Partners. This content was last updated in July 2026. For further information, visit Brain Cancer Australia.

Disclaimer: This material has been prepared by Hearts & Minds, published on July 1, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Picture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt Call
July 1, 2026

Next generation CAR T-cell therapy for cancer

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.

Read More
Picture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale Cohen
July 1, 2026

Revolutionising Diabetes Care

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Read More
HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).
May 4, 2026

How science turned back the clock of human development to create a miracle blood stem cell

Many thought it could never be done. But three Murdoch Children’s Research Institute scientists recreated embryonic development to crack the blood stem cell code.

Read More
November 15, 2024

Professor Alex Brown in conversation with Professor Jason Kovacic

At the 2024 Sohn Hearts & Minds Conference, we heard from Professor Alex Brown in conversation with Professor Jason Kovacic about Indigenous heart health and genomics.

Read More

A/Professor Tim Sargeant | 2024 Sohn Hearts & Minds Conference

Associate Professor Tim Sargeant has been at SAHMRI (South Australian Health and Medical Research Institute) in Adelaide where he studies the role of lysosomes in Alzheimer’s disease.

Read More
July 1, 2026

Unlocking the mysteries of the human brain

The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.

Read More
Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.
July 1, 2026

A new approach to Parkinson’s Disease

Exploring nerve stimulation as a potential treatment.

Read More
Dr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds Conference
July 1, 2026

Revealing what drives PSP

Mapping the biological changes behind progressive supranuclear palsy in the brain.

Read More
Picture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer Snaith
July 1, 2026

Advancing treatment options for type 1 diabetes

Improving blood glucose and reducing insulin needs.

Read More
Picture: Dr Hamish KingPicture: Dr Hamish KingPicture: Dr Hamish KingPicture: Dr Hamish King
July 1, 2026

Solving the genetic causes of autoimmune diseases

Mapping hundreds of risk markers to better understand how these diseases develop and progress

Read More
July 1, 2026

The Future of Pain Management

Enhancing healthcare professionals' ability to deliver better pain management, now and into the future.

Read More
July 1, 2026

Harnessing the power of stem cell technology

Developing cell therapies for patients with blood diseases

Read More
Picture: Professor Kazuaki NegishiPicture: Professor Kazuaki NegishiPicture: Professor Kazuaki NegishiPicture: Professor Kazuaki Negishi
July 1, 2026

Protecting the heart when every minute matters

Investigating a new treatment to reduce heart damage after heart attacks

Read More
Picture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio Vittorio
July 1, 2026

Targeting the drivers of cancer growth

Exploring how extrachromosomal DNA (ecDNA) drives cancer growth, spread and treatment resistance.

Read More
July 1, 2026

Improving the diagnosis of muscle disorders using advanced genetic testing

Focused on improving the efficiency and accuracy of diagnosing muscle disorders.

Read More